Houston-based CNS Pharmaceuticals is combining an unusual financing method with some interesting chemistry to expand the therapeutic choices for glioblastoma (GBM) patients.
The company is using crowdfunding to reach its ultimate goal is move their blood-brain barrier-penetrating chemotherapy, berubicin, into a phase 2 glioblastoma trial. Early preclinical results were promising and the phase I study showed the drug was well-tolerated and even hinted at efficacy. Berubicin has also been granted Orphan Drug status by the FDA in the US. It is the first of its class of drugs to cross the blood brain barrier (BBB) and reach cancer cells in brain tumor patients.
In 2018, with the funding to be secured from the crowdfunding campaign, CNS expects to commence its Phase 2(a) clinical trial of Berubicin for the treatment of GBM.
In late 2017, CNS entered into a collaboration agreement with Reata Pharmaceuticals to further advance the development of brain cancer technologies.